Jiahui Health and biotech firm partner to build CAR-T treament platform in China

The partnership promotes the sustainability of the CAR-T international treatment platform.

Jiahui Health and IASO Biotechnology said they will deepen their collaboration to jointly build a BCMA-targeted CAR-T Equecabtagene Autoleucel Injection treatment centre, which will focus on the development of the CAR-T international treatment platform.

In a joint statement, Jiahui Health said it will continue to focus on internationally advanced treatment concepts, medication, and technologies for the benefit of local and foreign patients in China.

Jiahui International Cancer Center launched an international CAR-T treatment team and carried out treatments in collaboration with various companies, including IASO Biotechnology and Fosun Kite. 

"In September, the first foreign lymphoma patient in China was treated with Akilenza Injection CAR-T and was successfully discharged from Jiahui International Hospital three weeks after completing the infusion," read the statement.

"In addition to the CAR-T patients who have been successfully discharged from the hospital after treatment, there are also a number of hematology-oncology patients from abroad who have chosen to undergo CAR-T treatment at Jiahui International Cancer Center," it added.